Indole-3-Carbinol Induces a G1 Cell Cycle Arrest and Inhibits Prostate-Specific Antigen Production in Human LNCaP Prostate Carcinoma Cells

Cancer

Volumn 98, Issue 11, 2003, Pages 2511-2520

  Zhang, Joann ^a   Hsu, Jocelyn C ^a   Kinseth, Matthew A ^a   Bjeldanes, Leonard F ^a   Firestone, Gary L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell cycle control; Cyclin dependent kinase; Gene expression; Growth inhibition; Indole 3 carbinol; Prostate carcinoma cells; Prostate specific antigen; Protein kinase activity

Indexed keywords

3 INDOLEMETHANOL; ANTIANDROGEN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DNA; ENZYME; FLUTAMIDE; PROPIDIUM IODIDE; PROSTATE SPECIFIC ANTIGEN; PROTEIN INHIBITOR; PROTEIN KINASE; PROTEIN P16; RETINOBLASTOMA PROTEIN; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; CELL COMPOSITION; CELL CYCLE G1 PHASE; CELL NUCLEUS; CELL PROLIFERATION; DNA SYNTHESIS INHIBITION; DOCUMENTATION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; STAINING; STIMULATION; WESTERN BLOTTING;

ANTICARCINOGENIC AGENTS; CARCINOMA; CYCLIN-DEPENDENT KINASES; FLOW CYTOMETRY; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0344844481     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11844     Document Type: Article

References (49)

1. Ruiter E, van de Kaa C, Miller C, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev. 1999;20:22-45.
2. Lopez-Otin C, Diamandis EP. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev. 1998;19:365-396.
3. Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett. 1987;214:317-322.
4. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145:907-923.
5. Vicini FA, Horwitz EM, Gonzalez J, Martinez AA. Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. J Urol. 1997;158:319-325.
6. Labrie F, Belanger A, Dupont A, Luu TV, Simard J, Labrie C. Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med. 1993;16:475-492.
7. Block G, Patterson B, Subar A. Fruit, vegetables and cancer prevention: a review of the epidemiological evidence. Nutr Cancer. 1992;18:1-29.
8. Jacobs DR, Marquart L, Slavin J, Kushi LH. Whole-grain intake and cancer: an expanded review and meta-analysis. Nutr Cancer. 1998;30:85-95.
9. Birt DF, Pelling JC, Nair S, Lepley D. Diet intervention for modifying cancer risk. Prog Clin Biol Res. 1996;395:223-234.
10. Chen I, Safe S, Bjeldanes L. Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Biochem Pharmacol. 1996;51:1069-1076.
11. Loub WD, Wattenberg LW, Davis DW. Aryl hydrocarbon hydroxylase induction in rat tissues by naturally occurring indoles of cruciferous plants. J Natl Cancer Inst. 1975;54:985-988.
12. Bradlow HL, Michnovicz J, Telang NT, Osborne MP. Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis. 1991;12:1571-1574.
13. Wattenberg LW, Loub WD. Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res. 1978;38:1410-1413.
14. Kojima T, Tanaka T, Mori H. Chemoprevention of spontaneous endometrial cancer in female Donryu rats by dietary indole-3-carbinol. Cancer Res. 1994;54:1446-1449.
15. Broadbent TA, Broadbent HS. The chemistry and pharmacology of indole-3-carbinol (indole-3-methanol) and 3-(methoxymethyl)indole. [Part II]. Curr Med Chem. 1998;5:469-491.
16. Broadbent TA, Broadbent HS. The chemistry and pharmacology of indole-3-carbinol (indole-3-methanol) and 3-(methoxymethyl)indole. [Part I]. Curr Med Chem. 1998;5:337-352.
17. Sharma S, Stutzman JD, Kelloff GJ, Steele VE. Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res. 1994;54:5848-5855.
18. Srivastava B, Shukla Y. Antitumour promoting activity of indole-3-carbinol in mouse skin carcinogenesis. Cancer Lett. 1998;134:91-95.
19. Cover CM, Hsieh SJ, Tran SH, et al. Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem. 1998;273:3838-3847.
20. Cover CM, Hsieh SJ, Cram EJ, et al. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res. 1999;59:1244-1251.
21. Cram EJ, Liu BD, Bjeldandes LF, Firestone GL. Indole-3-carbinole inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Spl transcription factor interactions with a composite element in the CDK6 promoter. J Biol Chem. 2001;276:22332-22340.
22. Nachshon-Kedmi M, Yannai S, Haj A Fares FA. Indole-3-carbinol and 3,3′-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol 2003;41:745-752.
23. Jeon KI, Rih JK, Kim HJ, et al. Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. FEBS Lett. 2003;544:246-251.
24. Agus DB, Cordon-Cardo C, Fox W, et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999;91:1869-1876.
25. Kibel AS, Isaacs WB. G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. Urology. 2000;55:316-322.
26. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000;60:3689-3695.
27. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
28. Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM. Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer. Prostate. 1999;39:8-15.
29. Macri E, Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev. 1998;17:337-344.
30. Shiraishi T, Watanabe M, Muneyuki T, et al. A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers. Urol Int. 1998;61:90-94.
31. Tsihlias J, Kapusta LR, DeBoer G, et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998;58:542-548.
32. Gartel AL, Tyner AL. Transcriptional regulation of the p21 (WAF1/CIP1) gene. Exp Cell Res. 1999;246:280-289.
33. Lee CT, Capodieci P, Osman I, et al. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res. 1999;5:977-983.
34. Yeh S, Miyamoto H, Nishimura K, et al. Retinoblastoma, a tumor suppressor, is a eoactivator for the androgen receptor in human prostate cancer DU145 cells. Biochem Biophys Res Commun. 1998;248:361-367.
35. Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res. 1997;57:4511-4516.
36. Lu S, Jenster G, Epner DE. Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol. 2000;14:753-760.
37. Chung LW, Zhau HE, Wu TT. Development of human prostate cancer models for chemoprevention and experimental therapeutics studies. J Cell Biochem Suppl. 1997;29:174-181.
38. Navone NM, Olive M, Ozen M, et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997;3:2493-2500.
39. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979;17:16-23.
40. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1978;21:274-281.
41. Lee C, Sutkowski DM, Sensibar JA, et al. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology. 1995;136:796-803.
42. Pang S, Taneja S, Dardashti K, et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther. 1995;6:1417-1426.
43. Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem. 2000;7:211-247.
44. Goldspiel BR, Kohler DR. Flutamide: an antiandrogen for advanced prostate cancer. Ann Pharmacother. 1990;24:616-623.
45. Dictor M, Ehinger M, Mertens F, Akervall J, Wennerberg J. Abnormal cell cycle regulation in malignancy. Am J Clin Pathol. 1999;112(1 Suppl 1):S40-52.
46. Costello JF, Plass C, Arap W, et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res. 1997;57:1250-1254.
47. Abrams P. Facts and future lines of research in prostate cancer: concluding remarks. BJU Int 2000;85 Suppl 2:49-51.
48. Harding MA, Theodorescu D. Prognostic markers in localized prostate cancer: from microscopes to molecules. Cancer Metastasis Rev. 1998;17:429-437.
49. Kim MR, Gupta MK, Travers SH, Rogers DG, Van Lente F, Faiman C. Serum prostate specific antigen, sex hormone binding globulin and free androgen index as markers of pubertal development in boys. Clin Endocrinol (Oxf). 1999;50:203-210.